Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 200

1.

Factors associated with tuberculosis-associated haemophagocytic syndrome: a multicentre case-control study.

Lerolle N, Laanani M, Galicier L, Rivière S, Meynard JL, Azoulay E, Jeblaoui A, Lalande V, Mougari F, Fardet L, Coppo P, Goujard C, Molina JM, Lambotte O.

Int J Tuberc Lung Dis. 2020 Jan 1;24(1):124-130. doi: 10.5588/ijtld.19.0856.

PMID:
32005316
2.

Anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura do not hamper ELISA-based quantification of ADAMTS13 antigen.

Dekimpe C, Roose E, Tersteeg C, Joly BS, Dewaele A, Horta S, Pareyn I, Vandenbulcke A, Deckmyn H, Feys HB, Tellier E, Kaplanski G, Scully M, Coppo P, De Meyer SF, Veyradier A, Vanhoorelbeke K.

J Thromb Haemost. 2020 Jan 27. doi: 10.1111/jth.14747. [Epub ahead of print]

PMID:
31989742
3.

Correction to: Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Azoulay E, Bauer PR, Mariotte E, Russell L, Knoebl P, Martin-Loeches I, Pène F, Puxty K, Povoa P, Barratt-Due A, Garnacho-Montero J, Wendon J, Munshi L, Benoit D, von Bergwelt-Baildon M, Maggiorini M, Coppo P, Cataland S, Veyradier A, Van de Louw A; Nine-i Investigators.

Intensive Care Med. 2020 Jan 21. doi: 10.1007/s00134-019-05904-7. [Epub ahead of print]

PMID:
31965263
4.

HLA-DRB1*11 is a strong risk factor for acquired thrombotic thrombocytopenic purpura in children.

Joly BS, Loiseau P, Darmon M, Leblanc T, Chambost H, Fouyssac F, Guigonis V, Harambat J, Stepanian A, Coppo P, Veyradier A.

Haematologica. 2020 Jan 16. pii: haematol.2019.241968. doi: 10.3324/haematol.2019.241968. [Epub ahead of print] No abstract available.

5.

Development of thrombotic thrombocytopenic purpura during lenalidomide therapy: three new cases and review of literature.

Elessa D, Talbot A, Lombion N, Harel S, Galicier L, Veyradier A, Joly B, Andreoli A, Rigaudeau S, Azoulay É, Coppo P, Royer B, Arnulf B.

Br J Haematol. 2020 Jan;188(2):338-340. doi: 10.1111/bjh.16333. Epub 2019 Dec 15. No abstract available.

PMID:
31840243
6.

HCV or HBV coinfection and lymphoma risk in people living with HIV.

Besson C, Noel N, Lancar R, Prevot S, Algarte-Genin M, Rosenthal E, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Cheret A, Arvieux C, Katlama C, Salmon D, Boué F, Costello R, Hendel-Chavez H, Taoufik Y, Fontaine H, Coppo P, Mounier N, Delobel P, Costagliola D; Lymphovir and FHDH study groups.

AIDS. 2019 Dec 10. doi: 10.1097/QAD.0000000000002461. [Epub ahead of print]

PMID:
31833850
7.

Association of dystrophic epidermolysis bullosa and neuroblastoma in a newborn.

Parodi E, Tirtei E, Bianchi M, Frigerio M, Morra I, Coppo P.

Pediatr Neonatol. 2020 Feb;61(1):117-118. doi: 10.1016/j.pedneo.2019.11.001. Epub 2019 Nov 13. No abstract available.

8.

Therapeutic plasma exchange in thrombotic thrombocytopenic purpura.

Picod A, Provôt F, Coppo P.

Presse Med. 2019 Nov;48(11 Pt 2):319-327. doi: 10.1016/j.lpm.2019.08.024. Epub 2019 Nov 20. Review.

PMID:
31759790
9.

Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura.

Graça NAG, Ercig B, Velásquez Pereira LC, Kangro K, Kaijen P, Nicolaes GAF, Veyradier A, Coppo P, Vanhoorelbeke K, Männik A, Voorberg J.

Haematologica. 2019 Nov 21. pii: haematol.2019.226068. doi: 10.3324/haematol.2019.226068. [Epub ahead of print]

10.

Amotosalen-inactivated fresh frozen plasma is comparable to solvent-detergent inactivated plasma to treat thrombotic thrombocytopenic purpura.

Garraud O, Malot S, Herbrecht R, Ojeda-Uribe M, Lin JS, Veyradier A, Payrat JM, Liu K, Corash L, Coppo P.

Transfus Apher Sci. 2019 Dec;58(6):102665. doi: 10.1016/j.transci.2019.10.007. Epub 2019 Nov 5.

11.

Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study.

Knoebl P, Cataland S, Peyvandi F, Coppo P, Scully M, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Minkue Mi Edou J, De Winter H, Callewaert F.

J Thromb Haemost. 2020 Feb;18(2):479-484. doi: 10.1111/jth.14679. Epub 2019 Dec 9.

PMID:
31691462
12.

Risk factors associated with the human leucocyte antigen system in Lebanese patients with immune-mediated thrombotic thrombocytopenic purpura.

Al Haddad C, Finianos P, Zgheib E, Germanos M, Coppo P.

Presse Med. 2019 Oct;48(10):1182-1184. doi: 10.1016/j.lpm.2019.09.009. Epub 2019 Oct 28. No abstract available.

PMID:
31672454
13.

Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Azoulay E, Bauer PR, Mariotte E, Russell L, Knoebl P, Martin-Loeches I, Pène F, Puxty K, Povoa P, Barratt-Due A, Garnacho-Montero J, Wendon J, Munshi L, Benoit D, von Bergwelt-Baildon M, Maggiorini M, Coppo P, Cataland S, Veyradier A, Van de Louw A; Nine-i Investigators.

Intensive Care Med. 2019 Nov;45(11):1518-1539. doi: 10.1007/s00134-019-05736-5. Epub 2019 Oct 7. Erratum in: Intensive Care Med. 2020 Jan 21;:.

PMID:
31588978
14.

Immune thrombotic thrombocytopenic purpura in older patients: prognosis and long-term survival.

Prevel R, Roubaud-Baudron C, Gourlain S, Jamme M, Peres K, Benhamou Y, Galicier L, Azoulay E, Poullin P, Provôt F, Maury E, Presne C, Hamidou M, Saheb S, Wynckel A, Servais A, Girault S, Delmas Y, Chatelet V, Augusto JF, Mousson C, Perez P, Halimi JM, Kanouni T, Lautrette A, Charvet-Rumpler A, Deligny C, Chauveau D, Veyradier A, Coppo P.

Blood. 2019 Dec 12;134(24):2209-2217. doi: 10.1182/blood.2019000748.

PMID:
31530564
15.

Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.

le Besnerais M, Veyradier A, Benhamou Y, Coppo P.

Expert Opin Biol Ther. 2019 Nov;19(11):1127-1134. doi: 10.1080/14712598.2019.1650908. Epub 2019 Aug 5.

PMID:
31359806
16.

Loss of von Willebrand factor high-molecular-weight multimers at acute phase is associated with detectable anti-ADAMTS13 IgG and neurological symptoms in acquired thrombotic thrombocytopenic purpura.

Béranger N, Benghezal S, Savigny S, Capdenat S, Joly BS, Coppo P, Stepanian A, Veyradier A.

Thromb Res. 2019 Sep;181:29-35. doi: 10.1016/j.thromres.2019.07.012. Epub 2019 Jul 16.

PMID:
31330376
17.

Thrombotic microangiopathy associated with anti-neutrophil cytoplasmic antibody-associated vasculitis: a French nationwide retrospective case-control study and literature review.

Dellal A, Bige N, Hilliquin P, Boffa JJ, Rondeau E, Hatron PY, Deligny C, Bally S, Maury E, Veyradier A, Buob D, Fain O, Coppo P, Mekinian A.

Rheumatology (Oxford). 2019 Oct 1;58(10):1873-1875. doi: 10.1093/rheumatology/kez167. No abstract available.

PMID:
31330026
18.

Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.

Poullin P, Bornet C, Veyradier A, Coppo P.

Drugs Today (Barc). 2019 Jun;55(6):367-376. doi: 10.1358/dot.2019.55.6.2989843. Review.

PMID:
31250841
19.

Rituximab Prevents Stroke Recurrences in Atypical Chronic Immune-Mediated Thrombotic Thrombocytopenic Purpura.

Dupuy H, Lazaro E, Machelart I, Viallard JF, Coppo P, Rivière E.

TH Open. 2018 Dec 5;2(4):e407-e410. doi: 10.1055/s-0038-1676357. eCollection 2018 Oct. No abstract available.

20.

An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura.

Joly BS, Coppo P, Veyradier A.

Expert Rev Hematol. 2019 Jun;12(6):383-395. doi: 10.1080/17474086.2019.1611423. Epub 2019 May 20.

PMID:
31107120
21.

Developments in the use of plasma exchange and adjunctive therapies to treat immune-mediated thrombotic thrombocytopenic purpura.

Picod A, Coppo P.

Expert Rev Hematol. 2019 Jun;12(6):461-471. doi: 10.1080/17474086.2019.1619170. Epub 2019 May 23.

PMID:
31092093
22.

Types of fresh plasma with focus on therapeutic plasma exchange.

Garraud O, Coppo P.

Transfus Apher Sci. 2019 Jun;58(3):258-261. doi: 10.1016/j.transci.2019.04.009. Epub 2019 Apr 19. Review.

PMID:
31036519
23.

When targeted therapies alleviate the burden of TPE: The example of immune-mediated TTP.

Picod A, Coppo P.

Transfus Apher Sci. 2019 Jun;58(3):273-277. doi: 10.1016/j.transci.2019.04.012. Epub 2019 Apr 19. Review.

PMID:
31018909
24.

Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma.

Crickx E, Poullot E, Moulis G, Goulabchand R, Fieschi C, Galicier L, Meignin V, Coppo P, Delarue R, Casasnovas O, Roos-Weil D, de Leval L, Parrens M, Michel M, Dupuis J, Le Bras F, Fataccioli V, Martin-Garcia N, Godeau B, Haïoun C, Gaulard P, Mahévas M.

Eur J Haematol. 2019 Jul;103(1):35-42. doi: 10.1111/ejh.13239. Epub 2019 May 30.

PMID:
30985955
25.

Inherited Thrombotic Thrombocytopenic Purpura Revealed by Recurrent Strokes in a Male Adult: Case Report and Literature Review.

Beauvais D, Venditti L, Chassin O, Joly B, Ameri A, Boisseau P, Lambotte O, Coppo P, Veyradier A, Denier C.

J Stroke Cerebrovasc Dis. 2019 Jun;28(6):1537-1539. doi: 10.1016/j.jstrokecerebrovasdis.2019.03.011. Epub 2019 Mar 28. Review.

PMID:
30930238
26.

Transfer of ADAMTS13 antibody-mediated thrombotic thrombocytopenic purpura via kidney transplantation.

Zafrani L, Dekimpe C, Joly BS, Roose E, Fieux F, Azoulay E, Peraldi MN, Durrbach A, Coppo P, Vanhoorelbeke K, Veyradier A.

Haematologica. 2019 Jun;104(6):e277-e280. doi: 10.3324/haematol.2019.219063. Epub 2019 Feb 28. No abstract available.

27.

Post-partum acute kidney injury: sorting placental and non-placental thrombotic microangiopathies using the trajectory of biomarkers.

Meibody F, Jamme M, Tsatsaris V, Provot F, Lambert J, Frémeaux-Bacchi V, Ducloy-Bouthors AS, Jourdain M, Delmas Y, Perez P, Darmian J, Wynckel A, Rebibou JM, Coppo P, Rafat C, Rondeau E, Frimat L, Hertig A.

Nephrol Dial Transplant. 2019 Feb 25. pii: gfz025. doi: 10.1093/ndt/gfz025. [Epub ahead of print]

PMID:
30805631
28.

Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine.

Coppo P, Cuker A, George JN.

Res Pract Thromb Haemost. 2018 Nov 16;3(1):26-37. doi: 10.1002/rth2.12160. eCollection 2019 Jan. Review.

29.

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators.

N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9.

30.

Generation of anti-idiotypic antibodies to detect anti-spacer antibody idiotopes in acute thrombotic thrombocytopenic purpura patients.

Schelpe AS, Roose E, Joly BS, Pareyn I, Mancini I, Biganzoli M, Deckmyn H, Voorberg J, Fijnheer R, Peyvandi F, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.

Haematologica. 2019 Jun;104(6):1268-1276. doi: 10.3324/haematol.2018.205666. Epub 2018 Dec 6.

31.

Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.

Daviet F, Rouby F, Poullin P, Moussi-Francès J, Sallée M, Burtey S, Mancini J, Duffaud F, Sabatier R, Pourroy B, Grandvuillemin A, Grange S, Frémeaux-Bacchi V, Coppo P, Micallef J, Jourde-Chiche N.

Br J Clin Pharmacol. 2019 Feb;85(2):403-412. doi: 10.1111/bcp.13808. Epub 2018 Dec 18.

32.

ADAMTS13 Gene Mutations Influence ADAMTS13 Conformation and Disease Age-Onset in the French Cohort of Upshaw-Schulman Syndrome.

Joly BS, Boisseau P, Roose E, Stepanian A, Biebuyck N, Hogan J, Provot F, Delmas Y, Garrec C, Vanhoorelbeke K, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies.

Thromb Haemost. 2018 Nov;118(11):1902-1917. doi: 10.1055/s-0038-1673686. Epub 2018 Oct 12.

PMID:
30312976
33.

EBV infection determines the immune hallmarks of plasmablastic lymphoma.

Gravelle P, Péricart S, Tosolini M, Fabiani B, Coppo P, Amara N, Traverse-Gléhen A, Van Acker N, Brousset P, Fournie JJ, Laurent C.

Oncoimmunology. 2018 Jul 30;7(10):e1486950. doi: 10.1080/2162402X.2018.1486950. eCollection 2018.

34.

Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.

Jestin M, Benhamou Y, Schelpe AS, Roose E, Provôt F, Galicier L, Hié M, Presne C, Poullin P, Wynckel A, Saheb S, Deligny C, Servais A, Girault S, Delmas Y, Kanouni T, Lautrette A, Chauveau D, Mousson C, Perez P, Halimi JM, Charvet-Rumpler A, Hamidou M, Cathébras P, Vanhoorelbeke K, Veyradier A, Coppo P; French Thrombotic Microangiopathies Reference Center.

Blood. 2018 Nov 15;132(20):2143-2153. doi: 10.1182/blood-2018-04-840090. Epub 2018 Sep 10.

PMID:
30201758
35.

Plasma for direct therapeutic use, for today and tomorrow: A short critical overview.

Garraud O, Aubron C, Ozier Y, Coppo P, Tissot JD.

Transfus Clin Biol. 2018 Nov;25(4):281-286. doi: 10.1016/j.tracli.2018.07.007. Epub 2018 Jul 26. Review.

PMID:
30131289
36.

Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review.

Guillot M, Rafat C, Buob D, Coppo P, Jamme M, Rondeau E, Fain O, Mekinian A.

Rheumatology (Oxford). 2018 Nov 1;57(11):2055-2057. doi: 10.1093/rheumatology/key228. Review. No abstract available.

PMID:
30101319
37.

A comprehensive analysis of Lymphoma-associated haemophagocytic syndrome in a large French multicentre cohort detects some clues to improve prognosis.

Bigenwald C, Fardet L, Coppo P, Meignin V, Lazure T, Fabiani B, Kohn M, Oksenhendler E, Boutboul D, Uzzan M, Lambotte O, Galicier L.

Br J Haematol. 2018 Oct;183(1):68-75. doi: 10.1111/bjh.15506. Epub 2018 Jul 24.

PMID:
30043391
38.

Plasma Exchanges for Refractory Evans Syndrome.

Pariente A, Joffre J, Fain O, Coppo P, Mekinian A.

Ther Apher Dial. 2018 Oct;22(5):560-562. doi: 10.1111/1744-9987.12682. Epub 2018 Jul 11. No abstract available.

PMID:
29998628
39.

Pediatric thrombotic thrombocytopenic purpura.

Joly BS, Coppo P, Veyradier A.

Eur J Haematol. 2018 Oct;101(4):425-434. doi: 10.1111/ejh.13107. Epub 2018 Aug 22. Review.

PMID:
29889319
40.

Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.

Hrdinová J, D'Angelo S, Graça NAG, Ercig B, Vanhoorelbeke K, Veyradier A, Voorberg J, Coppo P.

Haematologica. 2018 Jul;103(7):1099-1109. doi: 10.3324/haematol.2016.151407. Epub 2018 Apr 19. Review.

41.

Efficacy of eculizumab in an adult patient with HIV-associated hemolytic uremic syndrome: A case report.

Freist M, Garrouste C, Szlavik N, Coppo P, Lautrette A, Heng AE.

Medicine (Baltimore). 2017 Dec;96(51):e9358. doi: 10.1097/MD.0000000000009358.

42.

Expression of miRNA 155, FOXP3 and ROR gamma, in children with moderate and severe atopic dermatitis.

Bergallo M, Accorinti M, Galliano I, Coppo P, Montanari P, Quaglino P, Savino F.

G Ital Dermatol Venereol. 2017 Dec 15. doi: 10.23736/S0392-0488.17.05707-8. [Epub ahead of print]

PMID:
29249119
43.

An open conformation of ADAMTS-13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura.

Roose E, Schelpe AS, Joly BS, Peetermans M, Verhamme P, Voorberg J, Greinacher A, Deckmyn H, De Meyer SF, Coppo P, Veyradier A, Vanhoorelbeke K.

J Thromb Haemost. 2018 Feb;16(2):378-388. doi: 10.1111/jth.13922. Epub 2018 Jan 23.

44.

Nationwide survey on the use of eltrombopag in patients with severe aplastic anemia: a report on behalf of the French Reference Center for Aplastic Anemia.

Lengline E, Drenou B, Peterlin P, Tournilhac O, Abraham J, Berceanu A, Dupriez B, Guillerm G, Raffoux E, de Fontbrune FS, Ades L, Balsat M, Chaoui D, Coppo P, Corm S, Leblanc T, Maillard N, Terriou L, Socié G, de Latour RP.

Haematologica. 2018 Feb;103(2):212-220. doi: 10.3324/haematol.2017.176339. Epub 2017 Nov 23.

45.

Amotosalen-inactivated plasma is as equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange.

Guignier C, Benamara A, Oriol P, Coppo P, Mariat C, Garraud O.

Transfus Clin Biol. 2018 Feb;25(1):73-77. doi: 10.1016/j.tracli.2017.10.002. Epub 2017 Nov 2.

PMID:
29102655
46.

Amplified endogenous plasmin activity resolves acute thrombotic thrombocytopenic purpura in mice.

Tersteeg C, Joly BS, Gils A, Lijnen R, Deckmyn H, Declerck PJ, Plaimauer B, Coppo P, Veyradier A, Maas C, De Meyer SF, Vanhoorelbeke K.

J Thromb Haemost. 2017 Dec;15(12):2432-2442. doi: 10.1111/jth.13859. Epub 2017 Oct 27.

47.

Autoimmune manifestations associated with lymphoma: characteristics and outcome in a multicenter retrospective cohort study.

Jachiet V, Mekinian A, Carrat F, Grignano E, Retbi A, Boffa JJ, Ronco P, Rondeau E, Sellam J, Berenbaum F, Chazouillères O, Capron J, Alamowitch S, Chasset F, Frances C, Coppo P, Fain O; French Network of systemic and immune disorders associated with hemopathies and cancer (MINHEMON).

Leuk Lymphoma. 2018 Jun;59(6):1399-1405. doi: 10.1080/10428194.2017.1379075. Epub 2017 Oct 3.

PMID:
28972423
48.

[Hemolytic and uremic syndrome and related thrombotic microangiopathies: Treatment and prognosis].

Rafat C, Coppo P, Fakhouri F, Frémeaux-Bacchi V, Loirat C, Zuber J, Rondeau E.

Rev Med Interne. 2017 Dec;38(12):833-839. doi: 10.1016/j.revmed.2017.07.005. Epub 2017 Sep 22. Review. French.

PMID:
28947259
49.

Outcomes for HIV-associated diffuse large B-cell lymphoma in the modern combined antiretroviral therapy era.

Besson C, Lancar R, Prevot S, Algarte-Genin M, Delobel P, Bonnet F, Meyohas MC, Partisani M, Oberic L, Gabarre J, Goujard C, Boue F, Coppo P, Costello R, Hendel-Chavez H, Mekerri N, Dos Santos G, Recher C, Delarue R, Casasnovas RO, Taoufik Y, Mounier N, Costagliola D; ANRS-CO16 LYMPHOVIR Cohort.

AIDS. 2017 Nov 28;31(18):2493-2501. doi: 10.1097/QAD.0000000000001652.

PMID:
28926410
50.

[Secondary thrombotic microangiopathies].

Coppo P; Centre de référence des microangiopathies thrombotiques (CNR-MAT).

Rev Med Interne. 2017 Nov;38(11):731-736. doi: 10.1016/j.revmed.2017.06.025. Epub 2017 Sep 8. Review. French.

PMID:
28890263

Supplemental Content

Support Center